Results 51 to 60 of about 58,504 (176)

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. [PDF]

PLoS ONE, 2013
The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways.
Erica L Bradshaw-Pierce, Todd M Pitts, Gillian Kulikowski, Heather Selby, Andrea L Merz, Daniel L Gustafson, Natalie J Serkova, S Gail Eckhardt, Colin D Weekes   +8 more
doaj   +1 more source

The Protective Effect of Ethanolic Extract of Mentha spicata Against Irinotecan-Induced Mucositis in mice

Iraqi Journal of Pharmaceutical Sciences, 2019
Irinotecan induced-mucositis is an inflammatory event of intestine caused by an increase in concentration of active metabolite 7­ethyl­10-hydroxycamptothecin (SN­38) in the intestine. Irinotecan must first be converted by a carboxylesterase (CES) to the
Aliaa Abdul sattar Abdul jabbar, Sarmed H. Kathem   +1 more
doaj   +1 more source

Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China

BMJ Open, 2023
Objectives The hepatotoxicity of irinotecan has been widely implicated in the treatment of multiple solid tumours. However, there are few studies on the influencing factors of irinotecan-induced hepatotoxicity.
Yi Xu, Wei Li, Chengliang Zhang, Guangzhao He, Min Chen, Li Zhao, Jianhua Liu, Rui Huang, Zaoqin Yu, Qiuyan Song   +9 more
doaj   +1 more source

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

BMC Cancer
Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC.
Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman   +9 more
doaj   +1 more source

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

BMC Cancer, 2022
Background AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks.
S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts   +14 more
doaj   +1 more source

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

ESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku   +12 more
doaj   +1 more source

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system

Scientific Reports, 2020
We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model ...
Nathan McDannold, Yongzhi Zhang, Jeffrey G. Supko, Chanikarn Power, Tao Sun, Natalia Vykhodtseva, Alexandra J. Golby, David A. Reardon   +7 more
doaj   +1 more source

Patient data best-fit of irinotecan PK model.

, 2020
Each subplot represents an individual patient dataset, fit to the model independently. (A) shows the fit of irinotecan plasma concentration, (B) shows that of SN38, the active metabolite of irinotecan.
Roger J. W. Hill (8363451), Francis Lévi (4784820), Pasquale F. Innominato (8363454), Annabelle Ballesta (119580)   +3 more
core   +1 more source

The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. [PDF]

PLoS ONE, 2015
Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens. Mucositis causes cell damage, bacterial/endotoxin translocation and production of cytokines including IL-1 and IL-18.
Deysi V T Wong, Roberto C P Lima-Júnior, Cibele B M Carvalho, Vanessa F Borges, Carlos W S Wanderley, Amanda X C Bem, Caio A V G Leite, Maraiza A Teixeira, Gabriela L P Batista, Rangel L Silva, Thiago M Cunha, Gerly A C Brito, Paulo R C Almeida, Fernando Q Cunha, Ronaldo A Ribeiro   +14 more
doaj   +1 more source

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. [PDF]

, 2017
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC).
Chu, CM, Po-Li Wei, Chi-Ming Chu, Wei, PL, Precious Takondwa Makondi, Yu-Jia Chang, Makondi, PT, Chang, YJ   +7 more
core   +1 more source